Document Detail


Phase II trial of LY 186641 in advanced renal cancer.
MedLine Citation:
PMID:  7726992     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
LY 186641 is a diarylsulfonylurea with a broad spectrum antitumor activity against both murine and human solid tumors. We report here the results of a phase II trial of LY 186641 in advanced renal cell adenocarcinoma. The drug was administered orally, once daily for 2 weeks, every 21 days at a 700 mg/m2/d dose. Sixteen patients were enrolled in this phase II trial; 12 males, 4 females, with a median age of 58 years. All patients had progressive measurable metastatic disease. The primary tumor was surgically removed in all but one patient. Three patients were previously treated by biologic response modifiers (BRMs). A total of 72 courses were administered. The most common side effects were methemoglobulinemia (MetHgb) and anemia which occurred in 13 and 10 patients respectively. The MetHgb did not exceed 15%, and only 3 patients required blood transfusion for grade 3 (2 patients) and grade 4 (1 patient) anemia. Reversible hepatotoxicity was observed in 3 patients. There were one pathological complete response, seven stable disease and 8 progressive disease.
Authors:
M Mahjoubi; J Kattan; M Bonnay; H Schmitt; J P Droz
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Investigational new drugs     Volume:  11     ISSN:  0167-6997     ISO Abbreviation:  Invest New Drugs     Publication Date:  1993 Nov 
Date Detail:
Created Date:  1994-05-17     Completed Date:  1994-05-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  323-8     Citation Subset:  IM    
Affiliation:
Department of Medicine, Institut Gustave Roussy, Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Anemia / chemically induced
Antineoplastic Agents / administration & dosage,  adverse effects,  therapeutic use*
Carcinoma, Renal Cell / drug therapy*,  secondary
Drug Administration Schedule
Female
Humans
Kidney Neoplasms / drug therapy*
Male
Middle Aged
Sulfonylurea Compounds / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Sulfonylurea Compounds; 110311-27-8/sulofenur

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The envelope glycoprotein of HIV-1 alters NMDA receptor function.
Next Document:  Commonly asked questions about nightguard vital bleaching.